Closing
Do SGLT2 inhibitors improve cardiac & vascular function more than other treatments?
Mostly studied in coronary & atherosclerotic disease. Also asked versus placebo.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Unlikely. So far, the results disagree.
NoUnsureYes
- Belief
- 0.00 (range 0.00–0.55)
- Trials for
- 0
- Trials against
- 1
- Inconclusive
- 2
Already under way
- Randomized Trial of Sodium-glucose Cotransporter 2 Inhibition in Heart Transplant RecipientsNCT06625073 · recruiting · started 2026
- Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects in Patients Chronic Kidney Disease…NCT07304817 · recruiting · started 2026
- Assessment of the Effects of SGLT2 Inhibitors on Pericoronary Fat in Non-diabetic ACS Patients Without Heart Failure Using CCTANCT07351643 · not yet recruiting · started 2026
- The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan ProcedureNCT07482943 · recruiting · started 2026
- PRECISE Phenotyping to Guide Therapies for Coronary Microvascular DysfunctionNCT07533747 · not yet recruiting · started 2026
The evidence so far
- Registered trials
- 229
- With posted results
- 31
- Published papers
- 3
Of 26 decided analyses: 8 favor sglt2 inhibitors, 18 find no difference, 0 favor the comparator.
Papers
- Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE).Trial report · 2020
- Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.Trial report · 2021
- Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.Trial report · 2021
Trials
- A Phase III Randomised, Double-blind Trial to Evaluate the Effect of 12 Weeks Treatment of Once Daily EMPagliflozin 10 mg Compared With Placebo on ExeRcise Ability and Heart Failure Symptoms, In Patients With Chronic HeArt FaiLure With Preserved Ejection Fraction (HFpEF) (EMPERIAL - Preserved)NCT03448406 · 4 posted results
- A Phase III Randomised, Double-blind Trial to Evaluate the Effect of 12 Weeks Treatment of Once Daily EMPagliflozin 10 mg Compared With Placebo on ExeRcise Ability and Heart Failure Symptoms, In Patients With Chronic HeArt FaiLure With Reduced Ejection Fraction (HFrEF) (EMPERIAL-reduced)NCT03448419 · 4 posted results
- Randomized, Double Blind, Placebo Controlled, Multicenter Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF)NCT03200860 · 1 posted result
- A Randomized Active-Control Double-Blinded Study to Evaluate the Treatment of Diabetes in Patients With Systolic Heart FailureNCT02920918 · 1 posted result
- International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients With Preserved Ejection FractionNCT03877224 · 3 posted results
- International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients With Reduced Ejection FractionNCT03877237 · 3 posted results
- A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)NCT03057951 · 1 posted result
- A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)NCT03057977 · 1 posted result